Cantor Fitzgerald analyst Charles Duncan maintains $Axsome Therapeutics (AXSM.US)$ with a buy rating, and adjusts the target price from $107 to $121.
According to TipRanks data, the analyst has a success rate of 51.4% and a total average return of 24.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Axsome Therapeutics (AXSM.US)$'s main analysts recently are as follows:
Following a quarterly update that surpassed revenue expectations and provided promising pipeline developments, an analyst has acknowledged the clarification regarding the timeline of two concurrent Phase 3 Auvelity ADA trials. The simultaneous readouts expected in the fourth quarter clarify the forthcoming catalyst events. It is believed that achieving success in one of the two ADA trials may be sufficient to dispel any lingering concerns over regulatory outlooks for the crucial label expansion.
The third quarter of 2024 was notable for Axsome Therapeutics, mainly driven by a promising increase in Auvelity sales. The company remains a top selection due to the belief that it possesses the most compelling set of potential market influencers within the coverage universe through the end of the fourth quarter of 2024.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
坎托·菲茨杰拉德分析师Charles Duncan维持$Axsome Therapeutics (AXSM.US)$买入评级，并将目标价从107美元上调至121美元。
根据TipRanks数据显示，该分析师近一年总胜率为51.4%，总平均回报率为24.3%。
此外，综合报道，$Axsome Therapeutics (AXSM.US)$近期主要分析师观点如下：
在超过营业收入预期并提供有前景的管道发展的季度更新之后，一位分析师已经承认了有关两项同时进行的第三阶段Auvelity ADA试验时间表澄清。预计第四季度同时公布结果将澄清即将到来的催化事件。人们认为，在两项ADA试验中取得成功可能足以消除对关键标签扩展监管前景的任何顾虑。
2024年第三季度对axsome therapeutics来说是一个显著的季度，主要是由于Auvelity销售的有希望增长。由于人们认为该公司通过2024年第四季度结束前拥有最引人注目的潜在市场影响者组合，因此该公司仍然是首选。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
